Stryker Corporation (SYK) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $305.90, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-source suppliers; Weak growth.
Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and... Read more
Hold if already holding. Not a fresh buy at $305.90, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — Stryker Corporation
Latest news
- Stryker (NYSE:SYK) Sets New 12-Month Low - Time to Sell? - MarketBeat — MarketBeat negative
- M&T Bank Corp Lowers Stake in Stryker Corporation $SYK - MarketBeat — MarketBeat neutral
- Is It Fairly Priced Now | Stryker Corporation posts 3% EPS miss vs consensus - Revenue Guidance - Cổng thông tin điện tử — Cổng thông tin điện tử tỉnh Lào Cai negative
- Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Stryker Corporation $SYK - MarketBeat — MarketBeat positive
- Boston Trust Walden Corp Sells 6,108 Shares of Stryker Corporation $SYK - MarketBeat — MarketBeat neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole-source suppliers10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $305.90, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $350.41 (+14.6%), stop $287.80 (−6.3%), A.R:R 1.7:1. Score 5.5/10, moderate confidence.
Take-profit target: $350.41 (+14.2% upside). Target $350.41 (+14.6%), stop $287.80 (−6.3%), A.R:R 1.7:1. Stop-loss: $287.80.
Concentration risk — Supplier: sole-source suppliers; Weak growth; Below 200-MA, MA slope -2.8%/30d (confirmed downtrend).
Stryker Corporation trades at a P/E of 35.5 (forward 18.4). TrendMatrix value score: 5.2/10. Verdict: Hold.
37 analysts cover SYK with a consensus score of 4.1/5. Average price target: $389.
What does Stryker Corporation do?Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and...
Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and surgeons in approximately 61 countries. No commercial customer accounted for more than 10% of net sales in 2025.